Inhibrx says INBRX-106 plus Keytruda beats Keytruda alone in HNSCC data, with cancer-vaccine combination trials planned for early 2027.

Inhibrx announces impressive results for INBRX-106 in treating HPV-positive head and neck cancer, achieving a high response rate and significant progression-free survival metrics.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Reported Tuesday, Sep 8 - 7:36am EDT (TheFly subscription required to read more.)

First randomized OX40 agonist win in HNSCC still sparked a selloff. Investors questioned how broad the commercial opportunity really is.

Click to view the official SEC document.

Inhibrx announced positive results for its OX40-targeting immunotherapy INBRX-106, showing a 48% confirmed objective response rate compared to 27% for pembrolizumab alone. Median progression-free survival was 9.6 months for the combination therapy versus 4.9 months for the control arm. Shares rose in premarket trading after the experimental therapy outperformed Merck's Keytruda in head and neck cancer data.

Inhibrx Biosciences will host a live webcast to discuss primary results from the Phase 2 study of INBRX-106 for HNSCC, focusing on efficacy and safety.

The study compares INBRX-106 plus pembrolizumab with pembrolizumab alone in first-line patients; the webcast replay lasts 60 days.

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic...

Inhibrx Biosciences, Inc. has reported its financial results for the second quarter of 2026, detailing important developments in their clinical trials and financial outlook.

Inhibrx issued warrants for 21,457 shares at $93.21; the capital will support ozekibart and INBRX-106 ahead of key data readouts.

Inhibrx drug INBRX-106 with pembrolizumab boosted tumor response in head/neck cancer, showing higher shrinkage and immune activation.

Inhibrx is drawing strong interest from Merck and other big pharma for its experimental cancer drug INBRX-106 that could boost Keytruda. Potential $9B spin-off value.

Inhibrx Biosciences has reported positive interim data from the Phase II segment of its HexAgon study assessing INBRX-106 in treatment-naïve, PD-L1 positive metastatic or unresectable recurrent HNSCC.

Reported Monday, May 11 - 8:09am EDT (TheFly subscription required to read more.)

Reported Tuesday, Dec 16 - 5:05pm EST (TheFly subscription required to read more.)

Inhibrx recently shared interim Phase 2 trial results for INBRX-106, indicating significant improvements in response rates for HNSCC patients. The combination showed enhanced effectiveness over traditional monotherapy.

Inhibrx will host a live webcast on May 11, 2026, revealing interim results from the HexAgon study focusing on head and neck cancer therapy.

Inhibrx Biosciences provides significant progress updates on their clinical programs for INBRX-106 and ozekibart, aiming to enhance cancer treatment.

Inhibrx (Nasdaq: INBX) reported first quarter 2026 results and clinical updates for INBRX-106 and ozekibart (INBRX-109).Cash was $161.7 million, net loss was $33.4 million ($2.15 per share), and a BLA for ozekibart in conventional chondrosarcoma was submitted to the FDA.